Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 19/20 | 0.66 |
| ▸ | AVPR1A | P37288 | 19/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234753 | 0.92 | AVPR2 (0.69) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL3919632 | 0.92 | AVPR2 (0.65) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL4502013 | 0.92 | AVPR2 (0.76) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL14476330 | 0.90 | AVPR2 (0.59) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL8233213 | 0.90 | AVPR2 (0.60) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL4502304 | 0.90 | AVPR2 (0.62) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL8235373 | 0.90 | AVPR2 (0.62) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL3979687 | 0.89 | AVPR2 (0.60) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL3977873 | 0.89 | AVPR2 (0.60) | AVPR2AVPR1ATP53MAPT | |
| SCHEMBL8233642 | 0.89 | AVPR2 (0.60) | AVPR2AVPR1ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |